Trusopt Generic Drug
Therapeutic class: Ophthalmology
active ingredients: Dorzolamide
Eye drops in solution
Box of 1 bottle of 5 ml
· In addition to treatment with beta-blockers,
· As monotherapy in patients who do not respond to beta-blocker therapy or for whom beta-blockers are contraindicated.
For the treatment of high intraocular pressure in case of:
· Ocular hypertension,
· Open angle glaucoma,
· Capsular glaucoma (with pseudo-crystal exfoliation).
Dosage DORZOLAMIDE CHAUVIN 20 mg / ml Eye drops in solution Box of 1 vial of 5 ml
When DORZOLAMIDE CHAUVIN is used as monotherapy, the dosage is a drop in the conjunctival sac of the affected eye, three times a day.
When DORZOLAMIDE CHAUVIN is used in addition to a beta-blocker for ophthalmic use, the dosage is a drop in the conjunctival sac of the affected eye, twice a day.
When using DORZOLAMIDE CHAUVIN instead of another antiglaucoma, stop the antiglaucoma after taking it one last time, then start DORZOLAMIDE CHAUVIN the next day.
If you are using multiple ophthalmic medications on a local application, be sure to space administrations at least ten minutes apart.
Patients should avoid contact between the tip of the container and the eye or parts of the eye.
Patients should also be aware that if ophthalmic solutions are not handled properly, they may be contaminated with bacteria that cause eye infections. Using a contaminated solution can lead to serious eye damage and loss of vision.
Patients should be informed about the correct handling of the containers.
1. Wash your hands and then sit down or sit comfortably.
2. Unscrew the cap.
3. Tilt the head back and gently lower the lower eyelid of the affected eye.
4. Bring the tip of the container to the eye, avoiding contact.
5. Squeeze the container so that only one drop falls into the eye, then release the lower eyelid.
6. Repeat for the other eye if the doctor has told you.
7. Screw the cap back onto the container.
There are few clinical data regarding the use of dorzolamide three times daily in children. (For more information on the dosage in children, see the section on Pharmacodynamic properties ).
DORZOLAMIDE CHAUVIN is contraindicated in case of hypersensitivity to the active substance or to any of the excipients.
Dorzolamide has not been tested in patients with severe renal impairment (creatinine clearance <30 ml / min) or renal tubular acidosis. Since dorzolamide and its metabolites are mainly excreted by the kidney, DORZOLAMIDE CHAUVIN is contraindicated in these patients.
Side effects Dorzolamide Chauvin
Eye drops in 2% dorzolamide solution have been tested in more than 1, 400 individuals in controlled and uncontrolled clinical trials. Long-term studies of 1, 108 patients treated with dorzolamide alone or in combination with an ophthalmic beta-blocker demonstrated that the most common cause of discontinuation was treatment-related ocular adverse events in approximately 3 patients. % of patients, mainly conjunctivitis and inflammation of the eyelid.
The following side effects have been reported in clinical trials or post-marketing:
[Very common (≥ 1/10), common (≥ 1/100, <1/10), infrequent (≥ 1/1000, <1/100), uncommon (≥ 1/10 000, <1/1) 000)]
Nervous system disorders:
Rare: dizziness, paresthesia.
Very common: burning and stinging sensations.
Frequent: superficial punctate keratitis, tearing, conjunctivitis, eyelid inflammation, itchy eyelid, eyelid irritation, blurred vision.
Rare: irritation with redness, pain, crusts in the eyelid, transient myopia (which disappears when treatment is stopped), corneal edema, ocular hypotonia, choroidal detachment following filtration surgery.
Respiratory, thoracic and mediastinal disorders:
Frequent: nausea, feeling of bitterness in the mouth.
Rare: throat irritation, dry mouth.
Skin and subcutaneous tissue disorders:
Rare: contact dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Renal and urinary disorders:
General disorders and administration site defects:
Frequent: asthenia / fatigue.
Rare: hypersensitivity: signs and symptoms of local reactions (eyelid) and general allergic reactions including angioedema, urticaria and pruritus, rash, shortness of breath, rare cases of bronchospasm.
Biological tests: Dorzolamide has not been associated with clinically relevant electrolyte disorders.
See section Pharmacodynamic properties .